TY - JOUR
T1 - Alliance Against Cancer, the network of Italian cancer centers bridging research and care
AU - De, Paoli P
AU - Ciliberto, G
AU - Ferrarini, M
AU - Pelicci, P
AU - Dellabona, P
AU - De, Lorenzo F
AU - Mantovani, A
AU - Musto, P
AU - Opocher, G
AU - Picci, P
AU - Ricciardi, Walter
AU - De Maria Marchiano, Ruggero
PY - 2015
Y1 - 2015
N2 - Alliance Against Cancer (ACC) was established in Rome in 2002 as a consortium of six Italian comprehensive cancer centers (Founders). The aims of ACC were to promote a network among Italian oncologic institutions in order to develop speci c, advanced projects in clinical and translational research. During the following years, many additional full and associate members joined ACC, that presently includes the National Institute of Health, 17 research-oriented hospitals, scienti c and patient organizations. Furthermore, in the last three years ACC underwent a reorganiza-\r\ntion process that redesigned the structure, governance and major activities. The present goal of ACC is to achieve high standards of care across Italy, to implement and harmonize principles of modern personalized and precision medicine, by developing cost e ective processes and to provide tailored information to cancer patients. We herein summarize some of the major initiatives that ACC is currently developing to reach its goal, including tumor genetic screening programs, establishment of clinical trial programs for cancer patients treated in Italian cancer centers, facili- tate their access to innovative drugs under development, improve quality through an European accreditation process (European Organization of Cancer Institutes), and develop international partnerships. In conclusion, ACC is a growing organization, trying to respond to the need of networking in Italy and may contribute signi cantly to improve the way we face cancer in Europe.
AB - Alliance Against Cancer (ACC) was established in Rome in 2002 as a consortium of six Italian comprehensive cancer centers (Founders). The aims of ACC were to promote a network among Italian oncologic institutions in order to develop speci c, advanced projects in clinical and translational research. During the following years, many additional full and associate members joined ACC, that presently includes the National Institute of Health, 17 research-oriented hospitals, scienti c and patient organizations. Furthermore, in the last three years ACC underwent a reorganiza-\r\ntion process that redesigned the structure, governance and major activities. The present goal of ACC is to achieve high standards of care across Italy, to implement and harmonize principles of modern personalized and precision medicine, by developing cost e ective processes and to provide tailored information to cancer patients. We herein summarize some of the major initiatives that ACC is currently developing to reach its goal, including tumor genetic screening programs, establishment of clinical trial programs for cancer patients treated in Italian cancer centers, facili- tate their access to innovative drugs under development, improve quality through an European accreditation process (European Organization of Cancer Institutes), and develop international partnerships. In conclusion, ACC is a growing organization, trying to respond to the need of networking in Italy and may contribute signi cantly to improve the way we face cancer in Europe.
KW - Cancer care
KW - Clinical trials
KW - Italy
KW - Network of cancer centers
KW - Personalized medicine
KW - Translational research
KW - Cancer care
KW - Clinical trials
KW - Italy
KW - Network of cancer centers
KW - Personalized medicine
KW - Translational research
UR - https://publicatt.unicatt.it/handle/10807/111291
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84947422443&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84947422443&origin=inward
U2 - 10.1186/s12967-015-0711-x
DO - 10.1186/s12967-015-0711-x
M3 - Article
SN - 1479-5876
SP - N/A-N/A
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 13(360)
ER -